Turn on more accessible mode
Turn off more accessible mode
Skip to:
Content
|
Footer
|
Accessibility
This site
California
|
Home
Programs
Services
Health Information
Certificates & Licenses
Publications & Forms
Data
en Español
Su salud en su idioma
Most Popular Links
Birth, Death, & Marriage Certificates
Licensing and Certification
WIC
Quick Links
About Us
Decisions Pending & Opportunities for Public Participation
Diseases & Conditions
Job Opportunities
Local Health Services
Newsroom
Public Availability of Documents
Related Links
California Health and Human Services Agency
Department of Health Care Services (includes Medi-Cal)
State Agencies Directory
Home
>
Programs
Hepatitis C Guidelines
Hepatitis C Testing and Reporting Guidelines
Ortho Diagnostics CHIRON RIBA HCV 3.0 SIA Discontinuation Letter (March, 2013) (PDF, New Window)
Screening for Hepatitis C Virus in Adults: U.S. Preventive Services Task Force Recommendation Statement DRAFT (2012)
Hepatitis C Testing in Non-Health Care Settings, Guidelines for Site Supervisors and Testing Coordinators (CDPH, 2012) (PDF, New Window)
Recommendations for the Identification of Chronic Hepatitis C Virus Infection Among Persons Born During 1945–1965 (CDC, 2012)
Hepatitis B and Hepatitis C Screening and Serology Toolkit for Primary Care Clinicians (CDPH, 2012) (PDF, New Window)
Hepatitis C Case Definition - Past or Present (CDC, 2011)
Signal-to-Cutoff Ratios for Commercially Available Assays (CDC, 2008)
Interpretation of Hepatitis C Test Results (CDC) (PDF, New Window)
Hepatitis C Testing for Diagnosis Flow Chart (CDC) (PDF, New Window)
Laboratory Testing & Result Reporting of Antibody to Hepatitis C Virus (NCID, 2003)
Guidance for Industry: “Lookback” for Hepatitis C Virus (HCV): Product Quarantine, Consignee Notification, Further Testing, Product Disposition, and Notification of Transfusion Recipients Based on Donor Test Results Indicating Infection with HCV (FDA, 2010)
Office of AIDS Hepatitis C Testing Services Guidelines, 2007 (PDF, New Window)
Hepatitis C Prevention and Management Guidelines
PREP-C: Psychosocial Readiness Evaluation and Preparation for Hepatitis C Treatment
Incivek (telaprevir) product labeling revised (FDA, December 2012) (PDF, New Window)
FDA: PROMACTA® (eltrombopag) Label Updated (November, 2012)
Incivek (telaprevir) product labeling revised (FDA, June 2012)
Victrelis (boceprevir) and Ritonavir-Boosted Human Immunodeficiency Virus (HIV) Protease Inhibitor Drugs: Drug Safety Communication - Drug Interactions (FDA, 2012)
The 2012 Pipeline Report: HIV, Hepatitis C Virus (HCV), and Tuberculosis (TB) Drugs, Diagnostics, Vaccines, and Preventive Technologies in Development (Treatment Action Group)
SAMHSA Tip 53: Addressing Viral Hepatitis in People with Substance Use Disorders (SAMHSA, 2012) (New Window)
Updated Guidelines for Managing HCV, Genotype 1 (AASLD, 2011) (PDF, New Window)
Hepatitis Drug-Drug Interactions Tool (University of Liverpool, UK, 2011)
Diagnosis, Management, and Treatment of Hepatitis C (AASLD, 2009) (PDF, New Window)
NIH Consensus Statement: Management of Chronic Hepatitis C (2002)
National Hepatitis C Prevention Strategy (CDC, 2001)
Recommendations for Prevention and Control of Hepatitis C Virus (HCV) Infection and HCV-Related Chronic Disease (CDC, 1998) (PDF, New Window)
Prevent STDs Among MSM (CDC) (PDF, New Window)
LiverTox Database – Clinical and Research Information on Drug-Induced Liver Injury (NIH)
Last modified on: 4/24/2013 10:05 AM